NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
Clinical Trials
22 trialsNCT07259317 2026-03-27
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Corcept Therapeutics
Phase 2 Recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT06908304 2026-01-12
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
Phase 3 Recruiting
NCT01010945 2024-11-21
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT01318642 2024-11-08
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
NantBioScience, Inc.
Phase 2 Terminated
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04983407 2023-10-30
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
Aravive, Inc.
Phase 1/2 Terminated
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT02195180 2018-07-27
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
Phase 2 Completed
NCT01808638 2016-03-11
Atu027-I-02
Silence Therapeutics GmbH
Phase 1/2 Completed
NCT00998322 2015-04-10
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 2 Completed
NCT02194556 2014-07-18
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT01124786 2014-04-17
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Clovis Oncology, Inc.
Phase 2 Completed
NCT01830322 2013-08-14
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT00102700 2009-04-29
ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Completed
NCT00377936 2008-11-14
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
MediGene
Phase 2 Completed
NCT00358566 2008-05-19
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
Pharmexa A/S
Phase 3 Terminated
NCT00116389 2007-06-08
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
Point Therapeutics
Phase 2 Terminated
NCT00191503 2007-01-26
Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma
Eli Lilly and Company
Phase 2 Completed
NCT00042679 2006-07-19
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
Eli Lilly and Company
Phase 2 Completed